… More recently, however, Lee et al found that folic acid supplementation with B vitamins had
… SMP, B-KK, and BJ P were responsible for data interpretation and manuscript drafting. BC …

… (b) 40 TPM images were accumulated along the z-direction at the depth of ∼100–250 μm.
(c) 100× Magnification of CA3 regions at a depth of ∼120 μm. (d) Enlargement of the red box …

… rich in monomer A and in monomer B are formed. When microphase separation occurs, the
… block to that of the B block. Conformational asymmetry between A and B blocks also plays a …

Background Underweight, overweight, and obesity in childhood and adolescence are associated
with adverse health consequences throughout the life-course. Our aim was to estimate …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background Raised blood pressure is an important risk factor for cardiovascular diseases
and chronic kidney disease. We estimated worldwide trends in mean systolic and mean …

Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …

Background Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC)
have disease progression despite definitive chemoradiotherapy (chemotherapy …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …